Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oaktree Capital Management is a leading global alternative investment manager specializing in credit strategies and alternative assets. It manages over $200 billion in assets for institutional clients worldwide. The firm does not itself discover or commercialize drugs or healthcare products but has dedicated funds for life sciences lending and frequently invests in healthcare companies as part of its portfolio.
In July 2023, it closed the $2.3 billion "Oaktree Life Sciences Lending Fund," focused on private lending to biopharma and medical device companies. Recent investments include financing rounds for HealthCare.com and Verona Pharma's COPD drug launch.
The company was founded in 1995 by former TCW Group executives. In March 2019, Brookfield Asset Management acquired a majority stake.
Headquarters are in Los Angeles with offices globally including New York, London, Hong Kong, Tokyo, Paris, Frankfurt, Singapore, Seoul among others.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oaktree Capital Management.